$193.22
0.57%
NYSE, Oct 17, 10:09 pm CET
ISIN
US4781601046
Symbol
JNJ

Johnson & Johnson Stock price

$193.22
+16.02 9.04% 1M
+35.75 22.70% 6M
+48.60 33.61% YTD
+28.75 17.48% 1Y
+26.63 15.99% 3Y
+48.90 33.88% 5Y
+95.28 97.28% 10Y
+130.22 206.70% 20Y
NYSE, Closing price Fri, Oct 17 2025
+1.10 0.57%

Key metrics

Basic
Market capitalization
$465.3b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
18.7 | 17.6
P/S
5.0 | 4.9
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
$5.14
Yield 1Y | 5Y
2.7% | 2.9%
Growth 1Y | 5Y
4.7% | 5.3%
Payout 1Y | 3Y
84.8% | 53.6%
Increased
25 Years
Financials (TTM | estimate)
Revenue
$92.1b | $94.4b
EBITDA
- | $35.1b
EBIT
$24.9b | $30.9b
Net Income
$25.1b | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
5.1% | 6.2%
EBITDA
- | 13.7%
EBIT
3.0% | 31.6%
Net Income
71.1% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
68.2%
EBITDA
- | 37.2%
EBIT
27.0%
Net
27.3% | -
Free Cash Flow
-
Financial Health
Equity Ratio
39.7%
Return on Equity
19.7%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
$10.4
FCF per Share
-
Short interest
0.8%
Employees
138k
Rev per Employee
$640.0k
Show more

Create a Free Account to create an Johnson & Johnson alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Johnson & Johnson Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Johnson & Johnson forecast:

17x Buy
55%
14x Hold
45%

Analyst Opinions

31 Analysts have issued a Johnson & Johnson forecast:

Buy
55%
Hold
45%

Financial data from Johnson & Johnson

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
92,149 92,149
5% 5%
100%
- Direct Costs 29,349 29,349
9% 9%
32%
62,800 62,800
4% 4%
68%
- Selling and Administrative Expenses 23,376 23,376
5% 5%
25%
- Research and Development Expense 15,711 15,711
4% 4%
17%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 24,902 24,902
3% 3%
27%
Net Profit 25,119 25,119
71% 71%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Johnson & Johnson directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Johnson & Johnson Stock News

Neutral
PRNewsWire
about 16 hours ago
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors RARITAN, N.J. , Oct. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced promising new results fro...
Positive
MarketBeat
one day ago
Recent market speculation linking Johnson & Johnson NYSE: JNJ to a complete acquisition of its partner, Protagonist Therapeutics NASDAQ: PTGX, offers a valuable glimpse into a core corporate strategy. For a healthcare sector giant of Johnson & Johnson's scale, such moves are not about chasing short-term stock pops.
Positive
The Motley Fool
4 days ago
Jamison Private Wealth Management, Inc. disclosed a purchase of Johnson & Johnson shares valued at $6,762,412 in its SEC filing for the period ended Q3 2025, submitted on October 14, 2025.
More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office United States
CEO Joaquin Duato
Employees 138,100
Founded 1887
Website www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today